Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...
For adolescents with obesity, GLP1-RA treatment is associated with a reduced risk for suicidal ideation or attempts.
You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor ...
In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...
The use of glucagon-like peptide 1 (GLP-1) agonists in patients with inflammatory bowel disease (IBD) was associated with few ...
Ozempic is one of several medications, called glucagon-like peptide-1 receptor agonists or GLP-1 RAs, that are prescribed to treat diabetes, obesity, and other weight-related medical conditions.
Rybelsus is an oral glucagon-like peptide-1 (GLP-1) agonist and sibling medication to Ozempic and Wegovy. Per a phase 3 trial, Rybelsus was found to reduce cardiovascular risk among patients with ...
The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not ...
Eli Lilly and its investors this past week learned a hard lesson: The sky is no longer the limit when it comes to sales of its blockbuster glucagon-like peptide 1 (GLP-1) drugs for diabetes and ...